The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Open accessAbstract
Metabolic reprogramming is widely known as a hallmark of cancer cells to allow adaptation of cells to sustain survival signals. In this report, we describe a novel oncogenic signaling pathway exclusively acting in mutated epidermal growth factor receptor (EGFR) non‐small cell lung cancer (NSCLC) with acquired tyrosine kinase inhibitor (TKI) resistance. Mutated EGFR mediates TKI resistance through regulation of the fatty acid synthase (FASN), which produces 16‐C saturated fatty acid palmitate. Our work shows that the persistent signaling by mutated EGFR in TKI‐resistant tumor cells relies on EGFR palmitoylation and can be targeted by Orlistat, an FDA‐approved anti‐obesity drug. Inhibition of FASN with Orlistat induces EGFR ubiquitination and abrogates EGFR mutant signaling, and reduces tumor growths both in culture systems and in vivo. Together, our data provide compelling evidence on the functional interrelationship between mutated EGFR and FASN and that the fatty acid metabolism pathway is a candidate target for acquired TKI‐resistant EGFR mutant NSCLC patients. In EGFR mutated Non‐Small Cell Lung Carcinoma with acquired Tyrosine Kinase Inhibitors resistance, FASN mediates EGFR palmitoylation and supports tumor growth. With limited effective therapeutics, these data show that FASN is a candidate target for acquired TKI‐resistant EGFR mutant NSCLC. In EGFR mutated Non‐Small Cell Lung Carcinoma with acquired Tyrosine Kinase Inhibitors resistance, FASN mediates EGFR palmitoylation and supports tumor growth. With limited effective therapeutics, these data show that FASN is a candidate target for acquired TKI‐resistant EGFR mutant NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“FASN is important in the synthesis of palmitate, precursor of fatty acids, and is found frequently upregulated in many human cancers (Menendez & Lupu, 2007; Ogino et al, 2008; Migita et al, 2009).”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“Importantly, DNA analyses from PC-9GR ruled out the link between the development of acquired resistance to Gefitinib of PC-9GR cells and secondary EGFR T790M mutation, which is the most common mechanisms of acquired TKI resistance in NSCLC (Yun et al, 2008; Sequist et al, 2011).”
BackgroundYun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 1×
“A rationale for the differences seen in the functional impact of palmitoylation on EGFR is that the mutational status of EGFR may influence the functional role of palmitoylation on EGFR, as structural differences exist between wild-type and mutant EGFRs (Yun et al, 2007; Lowder et al, 2015).”
BackgroundPoliti, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478 · cited 1×
“The in vivo efficacy of Orlistat was further examined in the transgenic CCSP-rTTA-EGFR L858R-T790M-driven lung adenocarcinoma mouse model (Politi et al, 2006; Li et al, 2007).”
BackgroundBasolateral targeting by leucine‐rich repeat domains in epithelial cells
Legouis, R., Jaulin‐Bastard, F., Schott, S., Navarro, C., Borg, J., & Labouesse, M. (2003) · The EMBO Reports · doi:10.1038/sj.embor.7400006 · Cited by 153
A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2
Knowles, L. M., Axelrod, F., Browne, C. D., & Smith, J. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405061200 · Cited by 146
Cited by
Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
The role of lipids in cancer progression and metastasis
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 563
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Jin, H.-R., Wang, J., Wang, Z.-J., Xi, M.-J., Xia, B.-H., Deng, K., & Yang, J.-L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01498-2 · Cited by 481
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Metadata
- Authors
- Ali, A., Levantini, E., Teo, J. T., Goggi, J., Clohessy, J. G., Wu, C. S., Chen, L., Yang, H., Krishnan, I., Kocher, O., Zhang, J., Soo, R. A., Bhakoo, K., Chin, T. M., & Tenen, D. G.
- Venue
- EMBO Molecular Medicine
- Published
- 2018-02-15
- Volume
- 10
- Issue
- 3
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2788719551
- Cited by
- 187
- References
- 10
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer. https://app.cochat.ai/papers/10.15252/emmm.201708313
- The paper
- Ali, A., Levantini, E., Teo, J. T., Goggi, J., Clohessy, J. G., Wu, C. S., Chen, L., Yang, H., Krishnan, I., Kocher, O., Zhang, J., Soo, R. A., Bhakoo, K., Chin, T. M., & Tenen, D. G. (2018). Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201708313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.